Dr Knight on the Investigation of Patients With Brain-Metastatic Prostate Adenocarcinoma

Commentary
Video
Conference|ACRO Summit

James Knight, MD, discusses the potential launch of a case series of patients with brain-metastatic prostate adenocarcinoma.

James Knight, MD, resident, Radiation Medicine, the University of Kentucky College of Medicine, discusses the potential launch of a case series of patients with brain-metastatic prostate adenocarcinoma, highlighting the importance of the continued research regarding additional biomarkers which may improve the treatment landscape.

Related Videos
Somedeb Ball, MBBS
Lauren E. Nye, MD
Jonathan E. Rosenberg, MD
Emil Lou, MD, PhD, FACP
Jean L. Koff, MD, MS
Rohan Garje, MD
Debu Tripathy, MD
Benjamin Garmezy, MD
Jeffrey P. Townsend, PhD
Michael Iglesia, MD, PhD
Related Content
Erika Hamilton, MD

Vepdegestrant Plus Palbociclib Sustains Efficacy in Advanced ER+ Breast Cancer

May 16th 2024
Article
Neeraj Agarwal, MD

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

July 17th 2023
Podcast
Breast Cancer - stock.adobe.com

Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer

May 15th 2024
Article
Andrew J. Armstrong, MD, MSc

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

June 15th 2023
Podcast
Oluwaseun Orikogbo, MD

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

May 6th 2024
Article
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 6th 2024
Article